| CAPRICOR THERAPEUTICS |
| USA |
| Gesundheit |
| US14070B3096 / A2PLU4 |
| 4LN2 (Frankfurt) / CAPR (NASDAQ) |
| FRA:4LN2, ETR:4LN2, 4LN2:GR, NASDAQ:CAPR |
| - |
| https://capricor.com/ |
|
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases. Its lead program, Deramiocel, is an allogeneic cardiac-derived cell therapy being advanced for Duchenne mu..
>Volltext.. |
| 433.57 Mio. EUR |
| 305.13 Mio. EUR |
| - |
| -115.93 Mio. EUR |
| -112.75 Mio. EUR |
| -2.13 EUR |
| 79.32 Mio. EUR |
| 18.24 Mio. EUR |
| -90.6 Mio. EUR |
| 7.22 |
| -100% |
| -90.76% |
| - |
| - |
| - |
| - |
| CAPRICOR THERAPEUTICS, CAPRICOR THERAPEUTIC |
| 18.09.26 |
|
||||
|